STYXL1 and hepatocellular carcinoma: Increased MK-STYX mRNA expression results in upregulation of PI3K (phosphatidyl 3-kinase)/AKT pathway proteins and an enhancement of proliferation, while reducing apoptosis in hepatocellular carcinoma (Figure 6Bii) [33].